Stuttgart - Delayed Quote EUR

Valneva SE (AYJ.SG)

3.0340

+0.0500

+(1.68%)

At close: April 17 at 4:07:01 PM GMT+2

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IX

GlobeNewswire 3 hours ago

INRLF

VALN
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Saint-Herblain (France), April 16, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, D.C. Under the leadership of the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior managers will participate in multiple events, including an important presentation on the Compan

GlobeNewswire yesterday

INRLF

VALN
Valneva’s single-dose chikungunya vaccine authorised in Brazil

The authorisation paves the way for clinical studies to begin.

Pharmaceutical Technology 3 days ago

VLA.PA
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Saint Herblain (France), April 14, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The ANVISA decision marks the world’s first approval of a chikungunya vaccine in an endemic country. Part of Valneva’s endemic country str

GlobeNewswire 3 days ago

INRLF

VALN
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.

Zacks 8 days ago

VLA.PA

CTMX

ANIP
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate vaccine candidate against shi

GlobeNewswire 9 days ago

INRLF

VALN
Exploring Three High Growth Tech Stocks In Europe

The European market has recently experienced significant declines, with the pan-European STOXX Europe 600 Index dropping 8.44% amid heightened trade tensions and economic uncertainty stemming from new U.S. tariffs. In this challenging environment, identifying high growth tech stocks in Europe requires a focus on companies that demonstrate resilience through innovation and adaptability to evolving market conditions.

Simply Wall St. 10 days ago

BLV.PA

PHAR

PHGUF
Valneva SE Shareholding Declaration - March 2025

VALNEVA Declaration of shares and voting rights March 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 3, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change w

GlobeNewswire 14 days ago

INRLF

VALN
Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025?

We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Valneva (NASDAQ:VALN) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing Bell […]

Insider Monkey 16 days ago

VLA.PA
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint Herblain (France), April 1, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chiku

GlobeNewswire 16 days ago

INRLF

VALN
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) to potentially expand the use of its chikungunya vaccine, IXCHIQ®, currently approved in adults1, to adolescents aged 12 to 17 years in the UK. This submission follows the recent positive opinion of the European Medicine

GlobeNewswire 18 days ago

INRLF

VALN
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its registration statement on Form F-3, filed on March 25, 2025 with the U.S. Securities and Exchange Commission (“SEC”) relating to its existing At-the-Market offering facility (the “ATM Program”), which was originally entered into in August 2022 and has not been uti

GlobeNewswire 22 days ago

INRLF

VALN
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.25-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva’s 2024 Universal Registration Document – available in its entirety in French – includes the Company’s 2024 Annual Fina

GlobeNewswire 24 days ago

INRLF

VALN
Valneva outlays 40,000 vaccines to Réunion amidst chikungunya surge

Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Pharmaceutical Technology 24 days ago

VLA.PA
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ®. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreement

GlobeNewswire 25 days ago

INRLF

VALN
Valneva SE (INRLF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

Valneva SE (INRLF) reports robust sales growth and strategic advancements, while navigating regulatory delays and increased R&D expenses.

GuruFocus.com 28 days ago

VLA.PA
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private placement and 67% reduction in operating cash burnSubstantial clinical and regulatory progress in 2024; further data readouts, product approvals and label extensions anticipated in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments

GlobeNewswire 29 days ago

INRLF

VALN
High Growth Tech Stocks In Europe For March 2025

As European markets navigate the complexities of U.S. trade policy uncertainty and fluctuating economic indicators, the STOXX Europe 600 Index recently snapped a 10-week streak of gains, reflecting broader investor caution despite positive developments in Germany's defense and infrastructure spending. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience and adaptability to shifting market dynamics while capitalizing on...

Simply Wall St. last month

INRLF

VALN

BKHT.DE
VALNEVA Declaration of shares and voting rights: February 28, 2025

VALNEVA Declaration of shares and voting rights February 28, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 5, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change

GlobeNewswire last month

INRLF

VALN
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Saint-Herblain (France), March 3, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Bühler will present at the TD Cowen 45th Annual Health Care Conference, taking place March 3 - 5, 2025, in Boston, MA. Mr. Lingelbach and Mr. Peter Bühler will also meet with institutional investors during the Van Lanscho

GlobeNewswire last month

INRLF

VALN

Performance Overview

Return	AYJ.SG	CAC 40 (^FCHI)
YTD	+41.91%	-1.29%
1-Year	-15.72%	-8.72%
3-Year	-82.16%	+10.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Valneva SE (AYJ.SG)

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Valneva’s single-dose chikungunya vaccine authorised in Brazil

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Exploring Three High Growth Tech Stocks In Europe

Valneva SE Shareholding Declaration - March 2025

Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025?

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Valneva outlays 40,000 vaccines to Réunion amidst chikungunya surge

Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Valneva SE (INRLF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

High Growth Tech Stocks In Europe For March 2025

VALNEVA Declaration of shares and voting rights: February 28, 2025

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Performance Overview